Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma

Cancer

Volumn 117, Issue 21, 2011, Pages 4958-4965

  Verma, Jonathan ^a   Jonasch, Eric ^b   Allen, Pamela ^b   Tannir, Nizar ^b   Mahajan, Anita ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

brain metastasis; renal cell carcinoma; sorafenib; sunitinib; tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ERLOTINIB; GEMCITABINE; INTERFERON; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE;

ADRENAL METASTASIS; ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BRAIN SURGERY; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINAL NODE METASTASIS; METASTASIS; METASTASIS POTENTIAL; MONOTHERAPY; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROPERITONEAL NODE METASTASIS; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INCIDENCE; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES;

EID: 80054820244     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26138     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Yongping H, Xu J, Thun M,. Global cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Motzer RJ, Bander NH, Nanus DM,. Renal-cell carcinoma. N Engl J Med. 1996; 335: 865-875.
3. Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA,. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 1997; 37: 753-759. (Pubitemid 27181304)
4. Saitoh H,. Distant metastasis of renal adenocarcinoma. Cancer. 1981; 48: 1487-1491. (Pubitemid 11042605)
5. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13: 688-696.
6. Kim WY, Kaelin WG,. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004; 22: 4991-5004. (Pubitemid 46646218)
7. Rini BI, Small EJ,. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005; 23: 1028-1043. (Pubitemid 46202321)
8. Dvorak HF,. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002; 20: 4368-4380. (Pubitemid 35266299)
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007; 356: 115-124. (Pubitemid 46089672)
10. Escudier B, Eisen T, Stadler WM, for the TARGET Study Group, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134. (Pubitemid 46089673)
11. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
12. Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008; 113: 1641-1648.
13. Walid MS, Johnston KW,. Successful treatment of a brain-metastasized renal cell carcinoma. Ger Med Sci. 2009; 7: Doc28.
14. Helgason HH, Mallo HA, Droogendijk H, et al. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol. 2008; 26: 152-154.
15. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B,. Incidence of brain metastasis in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010; 21: 1027-1031.
16. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M,. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289-296. (Pubitemid 34032623)
17. Cox DR,. Regression models and life tables. J Royal Stat Soc Ser B. 1972; 34: 187-220.
18. StataCorp. Stata: Release 11. Statistical software. College Station, TX: StataCorp; 2009.
19. Vogl UM, Bojic M, Lamm W, et al. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. BMC Cancer. 2010; 10: 480.